“The successful outcome of this trial shows important progress for Orexo in building its proprietary pipeline. This is yet another important step towards our defined goal of becoming a specialty pharmaceutical company”
Orexo AB (STO:ORX) announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief.
Orexo plans to enter the next stage of development during the second half of 2011 following discussions with regulatory authorities.
Orexo currently has 3 fully owned programs (including OX51) in early stage clinical development, all directed towards hospital and specialist commercial segments. Initial data from OX219 was communicated in Q4 2010, and initial results from OX27 will be communicated during Q2 2011.
Anders Lundström, Orexo's President and CEO, said: "The successful outcome of this trial shows important progress for Orexo in building its proprietary pipeline. This is yet another important step towards our defined goal of becoming a specialty pharmaceutical company".
Small Solutions for Big Problems in Drug Discovery and Delivery